Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

Manuela Funke-Chambour; Namrata Kewalramani; Carlos Machahua; Venerino Poletti; Athol U Wells; Jacques Cadranel

doi:10.1183/23120541.00469-2022

Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation

ERJ Open Res. 2022 Dec 12;8(4):00469-2022. doi: 10.1183/23120541.00469-2022. eCollection 2022 Oct.

Authors

Manuela Funke-Chambour^{1

2}, Namrata Kewalramani¹, Carlos Machahua^{1

2}, Venerino Poletti³, Athol U Wells^{4

5}, Jacques Cadranel⁶

Affiliations

¹ Department for BioMedical Research DBMR, Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
³ Department of Thoracic Diseases, "G.B. Morgagni" Hospita, Forlì, Dipartimento di Medicina Specialistica Diagnostica e Sperimentale (DIMES) University of Bologna, Bologna, Italy.
⁴ Royal Brompton and Harefield NHS Foundation Trust, London, UK.
⁵ National Heart and Lung Institute, Imperial College London, London, UK.
⁶ Department of Pulmonary Medicine and Thoracic Oncology, Constitutive Reference Center of Rare Pulmonary Diseases, AP-HP, Hôpital Tenon and GRC04 Theranoscan, Sorbonne Université, Paris, France.

Abstract

The divergent views on lung cancer treatments in fibrosing lung patients reflect differences due to variable side-effect incidences in different countries and among ethnicities. International efforts are needed to better define treatment approaches. https://bit.ly/3DX40fq.